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Abstract 
Cytology is an easily accessible, cost-effective and safe procedure for the initial evaluation of 
most endocrine/neuroendocrine lesions. Both fine-needle aspiration cytology and exfoliative 
cytology have shown good sensitivity and specificity in detecting endocrine/neuroendocrine 
benign proliferations and malignancies. Thanks to its utility for early diagnosis, cytology has 
contributed to the decline in mortality of endocrine/neuroendocrine neoplasms.  
The endocrine system comprises different endocrine organs, such as the thyroid, adrenal 
glands, paraganglia, parathyroid, pancreas, hypothalamus, pituitary gland, ovaries and testes, 
which can give rise to non-neoplastic, benign and malignant proliferations. In addition, several 
neuroendocrine cells do not form specific endocrine organs, but are widely present along other 
systems, notably in the lungs and in the gastrointestinal tract. The general diagnostic approach 
to proliferations originating from neuroendocrine cells is similar to that of endocrine organs.  
In this review we concentrate on the cytological features of neuroendocrine proliferations, 
with particular emphasis on their most common sites of origin, i.e. the thyroid, pancreas, lungs 
and skin. We also discuss ancillary approaches applied to cytological material to improve the 
diagnosis. 
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Introduction 
The endocrine system can be virtually divided into the neuroendocrine (NE) and non-
neuroendocrine (non-NE) system. The latter includes follicular thyroid cells, adrenal cortical 
cells, and endocrine cells of the ovaries and testes. The NE system consists of hormone or 
amine secreting cells showing a neural-like phenotype. NE cells are typically immunoreactive 
for general neuroendocrine markers including chromogranin A (ChA), synaptophysin (Syp), 
CD56, and neuron-specific enolase (NSE).1, 2 They can be structured to form specific NE organs 
like the pituitary gland, parathyroid, paraganglia, and adrenal medulla or are dispersed (gut, 
lungs, skin and thyroid neuroendocrine cells – C cells) or grouped in small clusters (pancreatic 
islets) in other exocrine organs. It was initially thought that all NE cells originate from the neural 
crest, but it is now recognized that NE cells located in the lung and digestive system derive from 
endodermal stem cells.3   
Following the definition of the European Taskforce on Endocrine Cancer, endocrine (E) 
cancers are defined as malignant tumors arising in endocrine organs, like the thyroid, adrenal 
cortex, ovaries and the testes.4 Conversely, NE proliferations are defined as lesions originating 
from NE cells which give rise to lesions across the full spectrum applied to non-NE cells, ranging 
from hyperplasia and dysplasia to low grade malignant tumors and high grade neuroendocrine 
carcinomas, which are associated with different clinical aggressiveness and consequent 
therapeutic approach.  
Cytological examination is usually the first and most frequently used approach to obtain a 
clear diagnosis for any suspected proliferation or mass in the human body and this can also be 
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applied to NE proliferations. Cells can physiologically shed or desquamate within existing 
cavities or organs and can then be collected naturally or with aspiration (urine, sputum, ascites, 
cerebrospinal fluids), or they can be forced to desquamate with various procedures, such as in 
the case of bronchial aspiration/brushing or biliary duct brushing (exfoliative cytology). A 
sample of a lesion can also be collected by inserting a needle into it: this is the basis of fine-
needle aspiration cytology (FNAC), which is the most frequently used technique to investigate 
NE proliferations. In expert hands, FNAC is a safe, cost-effective and valuable approach.5 The 
accuracy of FNAC is higher if it performed under guidance by ultrasound (US) or computed 
tomography (CT).  
In this review we address the following topics: (i) We examine the morphological appearance 
of NE proliferations in endocrine organs and in non-endocrine organs, with particular attention 
to cases where cytology plays an important role in the diagnostic process; (ii) we analyze the 
most recent technical advances in FNAC; (iii) we discuss the role of ancillary techniques in the 
diagnostic process; and, finally, (iv) we discuss the classification cytology systems and their 
impact on the management of NE lesions. 
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1. Morphological aspects of NE proliferations. 
Apart from rare cases, such as in patients with known thyroid nodules associated with 
elevated plasma calcitonin levels or in patients with symptoms of specific endocrine syndromes 
(insulinoma, glucagonoma, carcinoid, Zollinger-Ellison, etc.), the clinical diagnosis of NE tumors 
is very rarely done pre-operatively. Thus cytopathologists should be aware of this possibility 
when examining cytological specimens, and possess a certain level of suspicion for these rare 
tumors.  
NE tumors present as a variable spectrum of lesions; from benign or low-grade 
malignant tumors to highly aggressive forms. Cytology, either alone or in conjunction with 
proliferation markers such as the Ki-67 index, can easily differentiate between the different 
forms. In general, cytomorphological features for NE tumors are well defined.6, 7   
For benign/low malignant tumors (variably called carcinoids, atypical carcinoids, or well 
differentiated NE tumors, according to the organ or origin and the classification system used) 
the most striking cytological feature is the presence of monotonous groups of cells with “salt 
and pepper” chromatin and absence of necrosis. Cells are monotonous in the sense that they 
are medium-sized and similarly shaped along the whole surface of the cytology slides. They are 
round, cuboidal or columnar in shape and can contain slightly granular and eosinophilic 
cytoplasm. Nuclei are round to oval, with a distinct nuclear membrane and characteristic “salt-
and-pepper” chromatin, defined as granular, hyperchromatic chromatin. Nuclear 
pleomorphism is moderate and molding (conformity of adjacent cell nuclei to one another) is 
usually absent. NE cells present predominantly as isolated cells or in small groups that are 
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defined as being trabecular, solid, or rosette-like. Trabecular groups are elongated structures of 
cells with slightly angulated borders. Solid groups are densely packed aggregates of cells with 
no visible lumen. Rosette-like groups are oval structures composed at the periphery by 
circularly positioned NE cells surrounding a lumen, thus resembling a rosette. Finally, the 
background of the slide is either clean or hemorrhagic. The key features which define low-grade 
malignant proliferations are the absence of necrosis, which confers a clean aspect to the slide, 
and the absence of mitotic activity (Table 1).  
High-grade malignant lesions (poorly differentiated NE carcinomas, small-cell and large-
cell type) also show characteristic morphological features. The slide background is dirty and 
occupied by necrotic debris, cellular ghosts and apoptotic bodies. Necrosis can be so abundant 
as to be the only feature present on the slide. Cells are usually isolated and discohesive; they 
can be small as well as large, spindle or fusiform. Cytoplasm is scant and the 
nuclear/cytoplasmic (N/C) ratio is increased, except in the large-cell variant. Nuclei are large 
with condensed and coarsely granular chromatin, that can present multinucleation and can 
show abundant mitotic figures, molding, apoptotic bodies and prominent nucleoli. Crushing 
artifacts are typical in more aggressive forms (Table 2).  
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2. Technical advances in FNAC of NE neoplasms 
The investigation of superficial and palpable lumps (especially in the thyroid) has 
traditionally been done with FNAC performed by simple palpation. However, the yield in terms 
of FNAC sampling was not very satisfactory. The advent of ultrasound (US ) examination not 
only increased the detection of thyroid (including medullary thyroid carcinomas, MTC) and 
parathyroid nodules, but it also radically increased the yield of diagnostic material.8 US-FNAC is 
currently the standard of care for the initial investigation of thyroid and liver nodules.9 
Reported sensitivity and specificity in distinguishing benign from malignant thyroid lesions was 
65% to 98% and 72% to 100%, respectively.10 
For the investigation of pulmonary and pancreatic masses, endobronchial ultrasound-
guided transbronchial needle aspiration (EBUS-TBNA) and endoscopic ultrasound FNA (EUS-
FNA), have been successfully introduced into daily clinical practice; these procedures are safe 
and they are increasingly replacing CT-guided FNAC.11 The sensitivity of EBUS-TBNA in the 
diagnosis of lung cancer is reported to be up to 90% after a necessary learning curve, while its 
diagnostic accuracy is higher than that of CT and PET (98% vs. 60.8% and 72.5%, respectively).12, 
13 The sensitivity of EUS-FNAC in diagnosing NE pancreatic lesions ranges from 84 to 94% and its 
specificity is as high as 95%.14, 15 The highest complication rate reported is 1.5% for EBUS-TBNA. 
Both procedures are minimally invasive, safe, cost-effective and are now considered the 
standard of care for the staging of lung cancers, and for the investigation of lung and pancreatic 
masses.16-19 The availability of skilled endoscopists is of primary importance to obtain high-
quality material. In our hospital, both EBUS-TBNA and EUS-FNA are performed in conjunction 
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with the cytological evaluation of the aspired material by a cytopathologist. This approach is 
called rapid on-site evaluation (ROSE). In our experience, this procedure increases the yield of 
the collected material and permits the best triage of the specimen. This is particularly 
important in case of suspected NE morphology during the rapid evaluation: in such a case, the 
cytopathologist asks for additional passes to realize a cytoblock, which is treated as a small 
biopsy and permits the testing for multiple immunocytochemical markers that are needed to 
confirm the NE diagnosis.13 Moreover, the adequate routing of aspired material done during 
the ROSE, permits the time before the final diagnosis to be shortened and the patient can be 
directed to the appropriate specialist more quickly. In our daily practice we use a linear 
endosonographic device with a 22- or 25-gauge needle. The first pass is used to prepare a 
smear that is rapidly (10 seconds) stained with toluidine-blue staining; we assess the quality of 
material and the possible diagnosis. In case of a suspected NE neoplasm, we use the second, 
third and even fourth pass to enrich the yield for the production of a cytoblock.  
Cytological examination is less reported for the identification of NE lesions originating 
from other NE organs. Pituitary and hypothalamic lesions are rarely diagnosed by cytology in 
the first instance; interestingly, we identified the cells of a pituitary carcinoma by cytological 
examination of cerebrospinal fluid, during an investigation for an invalidating headache (Figure 
1). Adrenal, ovarian and testicular proliferations can undergo US-guided FNA. Although 
pheochromocytomas and paragangliomas can be easy identified by cytology20, hypersecretion 
of catecholamines should be excluded before any biopsy of an adrenal mass or possible 
paraganglioma to avoid an adrenergic crisis. 
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3. Ancillary techniques in the diagnostic process  
Due to the complexity and peculiarity of the biology and treatment of NE neoplasms, a 
panel of immunocytochemical analyses should always confirm the cytological diagnosis.21 
Immunocytochemistry can be performed on classical smears, liquid-based preparations or 
cytoblocks. The first step of the diagnostic work-up in case of suspected NE lesions, irrespective 
of the site of origin, is to confirm the epithelial nature of the proliferation. For this, large-
spectrum cytokeratins are used, such as AE1/AE3. In poorly differentiated forms, such as 
pulmonary small-cell carcinomas, the lymphocytic marker CD45 is often used as well, as the 
differential diagnosis with a lymphoproliferative disorder may be difficult. The second step is 
the demonstration of a NE differentiation. The most frequently used NE markers are ChA and 
Syp; they are always used together and variably combined with CD56 or NSE. Among them, ChA 
is the most specific whilst synaptophysin is the most sensitive. CD56 and NSE have low 
sensitivity since they are expressed in several non-NE neoplasms (Figure 2 and 3). In selected 
cases, the Ki-67 proliferative marker is used to assess the fraction of proliferating cells, as this 
information is important for the classification (i.e. pancreatic NE tumors)(Figure 4).22  
Besides these general epithelial and NE markers, more specific organ-related 
immunocytochemical markers can be useful and applied routinely. In the thyroid, 
immunostaining for calcitonin (CT), carcinoembryonic antigen (CEA) and thyroglobulin (Tg) are 
mandatory to confirm the diagnosis (Figure 5). Indeed, MTC is positive for CT and CEA and 
negative for Tg, even if some rare exceptions do exist (i.e. the small-cell variant of MTC stains 
negatively for CgA).23 Moreover, the Congo red cytochemical staining for amyloid is very useful 
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on cytoblock material. In the lung, NE proliferations can secrete a variety of hormones that 
cause clinically evident paraneoplastic syndromes (syndrome of inappropriate secretion of 
antidiuretic hormone, syndrome of ectopic secretion of corticotropin-releasing hormone and 
syndrome of ectopic secretion of adrenocorticotropic hormone, ACTH). Some of these 
hormones can also be detected immunocytochemically in the NE cells such as ACTH, CT and the 
CT gene-related peptide, bombesin. Pancreatic NE tumors can be functioning or 
nonfunctioning. However, independently of the clinical presentation, a variety of hormones can 
be immunocytochemically detected in NE cells: the ones most frequently used in cytology are 
insulin, glucagon, somatostatin, gastrin, serotonin, ACTH and vasoactive intestinal peptide (VIP).  
In pancreatic NE tumors, somatostatin receptor type 2A can also be detected in cytological 
specimens.24 In the study of suspected parathyroid lesions (parathyroid adenomas and 
carcinomas), immunohistochemistry for parathyroid hormone (PTH) is very useful, as the 
morphological aspect of FNAC of parathyroid lesions is indistinguishable from the most 
common follicular-patterned thyroidal lesions. It is worth noting that routine FNAC of 
parathyroid lesions is not recommended as it can cause disseminated seeding of the cells 
leading to inoperable residual disease, termed “parathyromatosis”. In paragangliomas and 
pheochromocytomas, attention should be given to the negative expression of cytokeratins, 
which are conversely expressed by almost all other NE tumors. A positive immunocytochemical 
staining for S-100 protein, which is expressed in sustentacular cells, confirms the diagnosis.21 In 
the skin, Merkel cell carcinomas shows a characteristic paranuclear and dot-like cytokeratin-20 
expression, as well as negativity for TTF-1.  
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In cases of metastatic NE tumors, notably to the liver, and in the absence of a known 
primary lesion, a combination of different immunocytochemical markers and hormonal markers 
can be helpful to establish the site of origin of the metastasis. Duan et al. proposed an 
algorithmic approach for the determination of the site of origin in cases of well differentiated 
NE tumors, combining thyroid transcription factor 1 (TTF-1), caudal type homeobox 2 (CDX-2), 
insulin gene enhancer protein (Islet-1), pancreatic and duodenal homeobox 1 (PDX-1) and 
prostatic acid phosphatase (PAP).21 However, these markers are only useful in the diagnostic 
work-up of well differentiated neoplasms, because their expression in poorly differentiated 
neuroendocrine carcinomas does not respect the site of origin. 
 
 
4 . Cytological classification and management of NE tumors 
An internationally accepted cytology classification scheme exists only for pancreatic and 
thyroid tumors.25, 26 The Papanicolaou Society of Cytopathology recommended the use of a six-
tiered diagnostic category system (Table 3) for pancreatic lesions.  It is also recommended to 
adhere to this classification for NE pancreatic tumors. In the majority of cases, well 
differentiated pancreatic NE tumors are classified in the “neoplastic category”, under the 
specification “other”. One motivation for not classifying well differentiated/low grade 
pancreatic NE tumors in either the benign or the malignant diagnostic category is to allow a 
broad choice of management options for these lesions in accordance with the clinical-
pathological situation (e.g. age and general health condition of the patient, clinical hormonal 
symptoms, size and proliferation rate of the lesion, compression of other structures). In cases 
12 
 
of suspected more aggressive neoplasms, showing necrosis, mitotic activity or high grade 
atypia, the most appropriate cytological diagnosis is “suspicious” or “positive”. 
For MTC, as for the other thyroids neoplasms, the classification system widely used is The 
Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). MTC are usually classified into 
the diagnostic category V (suspicious for malignancy) or VI (malignant) (Table 4). Both 
categories have high malignancy risks (60 to 75% and 97 to 99%, respectively) that justify a 
surgical approach.  
The management of others NE tumors varies according to the site of origin. Several 
guidelines have been published by expert pathologists and clinicians, and are available on the 
website of the European Neuroendocrine Tumor Society (ENETS).27 A consensus on the 
diagnosis and treatment has been difficult to reach in some cases, due to the limited evidence 
available in the literature for these rare tumors. Generally, if the tumor is resectable, surgery is 
the first line of treatment. In advanced cases, other options for local and/or systemic therapy 
can be considered.  
It is noteworthy to remember that in several cases, the cytological material may represent 
the only source of tumor tissue for diagnostic purposes; thus appropriate biobanking and tissue 
preservation is strongly recommended to facilitate the use of new diagnostic tools and patient-
tailored future therapies. 
 
5. Conclusions 
In conclusion, cytology remains the most accurate (and sometimes the only) diagnostic 
approach to the initial management of NE lesions. Furthermore, the application of 
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immunocytochemical staining and the use of the proliferation index is fundamental for the 
appropriate classification and consequent management, for patients suffering NE diseases.    
 
14 
 
Figure legends 
 
Figure 1. Pituitary carcinoma with growth hormone expression in cerebrospinal fluid (CSF). 
 This was the case of a 16-year-old female presenting with severe headaches, vertical diplopia, 
and nausea for the previous 6 days. Neurological examination showed partial deficit of the third 
pair of cranial nerve ptosis and diplopia. Endocrinological examination revealed hypocorticism 
and hypothyroidism. A sellar IRM was performed showing a 2.7 cm sellar mass. Clinically, the 
possible diagnoses were hypophysary apoplexia or a craniopharingioma.   Cerebrospinal fluid 
analysis and resection of the mass were performed.  A. CSF examination showed a monotonous 
group of bland-appearing cells (arrows) along with amorphous debris (Cytospin preparation, 
Papanicolaou staining, 200x). B. The cell block preparation showed the same population of cells 
with abundant eosinophilic cytoplasm (Hematoxylin and Eosin staining, 200x). C. Cells in the 
cytoblock were intensely positive for the growth hormone and only scattered cells showed 
prolactin expression (Inset, immunohistochemical staining, 200x). LH, TSH, ACTH and HCG were 
all negative. The final cytological diagnosis was: cerebrospinal fluid infiltrated by a pituitary 
carcinoma with GH diffuse expression in immunocytochemistry. D. The resection specimen 
showed a monomorphic proliferation of cells with a lack of a reticulin network among 
neoplastic cells and was consistent with a pituitary carcinoma with GH expression (Hematoxylin 
and Eosin staining, 100x). 
 
Figure 2. Immunocytochemical panel used as the first line diagnosis of neuroendocrine lung 
tumors in cases of suspicious morphology.  
In this case, a 71-year-old male was investigated for multiple mediastinal adenopathy following 
weight loss and cough. A. EBUS-TBNA of lymph node station 11R was performed and showed a 
densely packed group of small cells, with scant cytoplasm and dark nuclei. Associated are small 
lymphocytes (arrows) and macrophages (arrow head) demonstrating that the FNA was 
performed in a lymph node (Papanicolaou staining, Liquid-based preparation, 600x). B. The cell 
block preparation showed the same population of small cells with some more spindled 
elements, a high mitotic activity (arrow heads indicate mitosis) necrosis (asterisks) and some 
scattered lymphocytes (arrows). The differential diagnosis is between a small cell lung 
carcinoma metastatic to a lymph node and a lymphoma (Cell block preparation, Hematoxylin 
and Eosin staining, 600x). C. shows dot-like positivity (arrows) of malignant cells for cytokeratin 
MNF116, an intense cytoplasmic positivity of normal bronchial cylindrical cells (asterisks) for 
the same immunocytochemical marker and negativity of all other cells present (lymphocytes 
and macrophages) (immunocytochemical staining, 600x). D. Conversely, CD45 shows negativity 
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in malignant cells (asterisks) and scattered positive lymphocytes (arrows) demonstrating the 
epithelial nature of the malignant proliferation (immunocytochemical staining for CD45, 600x).  
Other markers should then be used to prove the neuroendocrine nature of the malignant cells, 
such as E. Chromogranin A (immunocytochemical staining, 400x), F. Synaptophysin 
(immunocytochemical staining, 600x), both with granular para-nuclear positivity and G. CD56 
(immunocytochemical staining, 600x). H. In the case of lung neuroendocrine carcinoma, the 
proliferation index (ki-67) is not necessary for classification, but is used to demonstrate the 
highly proliferative activity of the lesion (in this case 50% of cells are proliferating), thus 
confirming the diagnosis (immunocytochemical staining, Mib-1 antibody, 600x). The final 
cytopathological diagnosis was: metastatic small cell neuroendocrine carcinoma.  
 
Figure 3. Large cell neuroendocrine carcinoma of the lung. 
 A 65-year-old female with a history of smoking and chronic obstructive pulmonary disease was 
discovered with a lung mass and multiple adenopathies and investigated with EBUS-TBNA of 
Barety’s space lymph nodes. A. Cytological smears showed isolated malignant large cells, with 
scant cytoplasm, dark and nucleated nuclei (Smear, Papanicolaou staining, 600x). B.  A different 
smear showed the typical polymorphous and atypical nuclei and the molding aspect of the 
delicate chromatin (Smear, Papanicolaou staining, 600x). C.  Smears can also be used to 
perform immunocytochemical staining, showing in this slide positive para-nuclear and dot-like 
expression for Chromogranin A (immunocytochemical staining, 600x). D. The cell block was 
used to biobank the material in case of future additional testing. Large cells were present 
(arrows) as well as necrosis (asterisk) and normal lymphocytes (arrow heads) (Cell block 
preparation, Hematoxylin and Eosin staining, 600x). The final cytopathological diagnosis was: 
metastatic large cell neuroendocrine carcinoma.  
 
Figure 4. Pancreatic neuroendocrine proliferations. 
 A 72-year-old male with chronic diarrhea was discovered to have a pancreatic mass in the 
head.  EUS-FNAC with ROSE evaluation by a cytopathologist was performed in the pancreatic 
lesion. A. Cytological ROSE smears showed isolated tumoral cells with scant cytoplasm, and 
nucleated nuclei. Blood is present in the background of the slide. Note the poor quality of the 
staining, being performed in 10 seconds for rapid evaluation and assessment. Following the 
cytological ROSE examination (suspicion of a neuroendocrine proliferation), additional passes 
were performed to create a rich cell block (Smear, Toluidine blue, 600x). B. The cell block 
preparation showed the same monotonous proliferation of cells, with moderate cytoplasm. 
Nucleoli are present and necrosis is absent (Cell block preparation, Hematoxylin and Eosin 
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staining, 600x). C. The neuroendocrine nature of the lesion was demonstrated by the intense 
and cytoplasmic expression for Chromogranin A (immunocytochemical staining, 600x). D. the 
proliferation index (ki-67) is necessary for grading and classification. In this case less than 1% of 
cells are proliferating, thus confirming the low grade nature of the tumor (immunocytochemical 
staining, Mib-1 antibody, 100x). The final cytopathological diagnosis was: pancreatic well 
differentiated neuroendocrine tumor (NET), G1. Inset shown for comparison: a different case of 
pancreatic neuroendocrine proliferation with Ki-67 index around 80%. In this case the diagnosis 
is pancreatic poorly differentiated neuroendocrine carcinoma (NEC), G3 (immunocytochemical 
staining, Mib-1 antibody, 200x). 
 
Figure 5. FNAC of a medullary thyroid carcinoma. 
A 37-year-old female with an unremarkable medical history presented with a small pre-tracheal 
nodule, probably originating from the thyroid. It was described as “not very suspicious” by the 
endosonographer. A. The smear was hypercellulated (Smear, Papanicolaou staining, 100x) and 
also contained scattered amorphous material, suspicious to be amyloid (Inset, Papanicolaou 
staining, 600x). B. Malignant cells were large with abundant and granular cytoplasm, organized 
in ribbons and nuclei presented pseudoinclusions (arrows). The chromatin of the other cells 
was granular (Smear, Papanicolaou staining, 600x). C. The cell block showed the same 
morphological characteristics of the smear and an organoid growth pattern. 
Immunocytochemical staining performed on the smears showed (D) intense expression for 
Calcitonin and (E) focal expression for Chromogranin A (immunocytochemical staining, 200x).  
The final cytopathological diagnosis was: medullary thyroid carcinoma. F. The histological 
specimens showed a trabecular / insular pattern of growth (Hematoxylin and Eosin staining, 
200x) and an intense expression for calcitonin, while the surrounding normal thyroid 
parenchyma was negative (asterisks) (Inset, immunohistochemical staining, 100x). 
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Table 1: Main cytomorphological features of benign/low malignant potential neuroendocrine 
tumors. 
Background Clean or hemorrhagic 
Cellularity Highly cellular smear, monotonous cells isolated 
or in aggregates (trabecular, solid, rosette-like) 
Cytoplasm Granular and eosinophilic; low N/C ratio  
Cell Medium sized cells with polygonal/cuboidal 
appearance 
Nuclei Nuclei round to oval with “salt & pepper” 
chromatin, regular nuclear membrane 
N/C: nuclear/cytoplasmic  
 
Table 2: Main cytomorphological features of well differentiated/malignant neuroendocrine 
carcinomas. 
Background Hemorrhagic and/or necrotic 
Cellularity Highly cellular smear, polymorphous cells isolated 
or in irregular aggregates 
Cytoplasm Inconspicuous with high N/C ratio in small cell 
carcinomas; abundant in large cell carcinomas 
with low N/C ratio  
Cell All possible sized cells with monstrous 
appearance 
Nuclei Nuclei enlarged, polymorphous, bizarre, 
multinucleated, “salt & pepper” chromatin, 
irregular nuclear membrane, multiple mitotic 
figures 
 
 
Table 3: The classification systems for reporting pancreatobiliary cytology. Most well 
differentiated NE tumors fall into the neoplastic category, while poorly differentiated NE 
tumors fall in the suspicious or positive/malignant category (modified by: Pitman MB et al.).25 
 
Diagnostic category 
Non-diagnostic 
Negative 
Atypical 
Neoplastic (benign or other) 
Suspicious 
Positive/malignant  
 
Table 4: The classification systems for reporting thyroid cytology know as The Bethesda 
System for Reporting Thyroid Cytopathology. Thyroid medullary carcinomas are usually 
diagnosed in the diagnostic category V and VI (modified by Ali and Cibas).26 
Diagnostic category Risk of 
malignancy, % 
Usual management 
I. Non-diagnostic or unsatisfactory 1-4 Repeat FNA with ultrasound 
guidance 
II. Benign 0-3 Clinical follow-up 
III. AUS/FLUS 5-15 Repeat FNA 
IV. FNS/SFN 15-30 Lobectomy  
V. Suspicious for malignancy 60-75 Near-total thyroidectomy or 
lobectomy 
VI. Malignant 97-99 Near-total thyroidectomy 
 
Figure 1. Pituitary tumor with growth hormone expression in CSF  
A B 
C D 
* 
Figure 2. Lung small cell NE carcinoma, EBUS 
A B 
C D 
E F 
G H 
* 
* 
Figure 3. Lung large cell NE carcinoma, EBUS 
* 
C D 
A B 
Figure 4. Pancreatic well differentiated NE tumor (NET), G1, EUS 
A B 
C D 
Figure 5. Thyroid medullary carcinoma, fine-needle aspiration 
* * 
A B 
C D 
E F 
